

cyclomedica technegas cyclopet ultralute

30 May 2025

The Manager Company Announcements Office Australian Securities Exchange Limited 20 Bridge Street Sydney NSW 2000

Cyclopharm Ltd ABN 74 116 931 250 Unit 4, 1 The Crescent Kingsgrove NSW 2208 Australia T 61 2 9541 0411 F 61 2 9543 0960 www.cyclopharm.com.au

## **Results of Annual General Meeting on 30 May 2025**

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise that all resolutions put forth to the shareholders were duly passed.

Details of the resolutions and the proxies received in respect of each resolution are set out in the attached voting results summary.

Janes & MCBreyer

James McBrayer Managing Director and Company Secretary

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

## For more information, please contact:

Mr James McBrayer Managing Director, CEO and Company Secretary Cyclopharm Limited T: +61 (02) 9541 0411 M:+61 (0) 0418 967 073

## **Disclosure of Proxy Votes**

**Cyclopharm Limited** Cyclopharm Limited - 2025 Annual General Meeting Friday, 30 May 2025



In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes			Poll Results (if applicable)			Results	
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Remuneration Report	Ρ	59,515,880	59,178,529 99.43%	283,084 0.48%	4,182	54,267 0.09%	60,060,708 99.53%	283,084 0.47%	31,398	-
2 Re-election of Director	Ρ	62,559,799	62,476,956 99.87%	27,700 0.04%	12,500	55,143 0.09%	63,464,706 99.96%	27,700 0.04%	12,500	Carried
3 Approval of grant of performance rights	Ρ	59,825,529	59,314,524 99.15%	460,862 0.77%	2,746,770	50,143 0.08%	60,292,381 99.24%	460,862 0.76%	2,773,986	Carried
4 Approval of grant of performance rights to the Managing Director for FY25 STI	Ρ	59,976,637	59,465,632 99.15%	461,556 0.77%	2,595,662	49,449 0.08%	60,442,795 99.24%	461,556 0.76%	2,622,878	Carried
5 Approval of grant of performance rights to the Managing Director for FY25 LTI	Ρ	59,976,637	54,564,667 90.98%	5,362,703 8.94%	2,595,662	49,267 0.08%	55,541,648 91.19%	5,362,703 8.81%	2,622,878	Carried
6 Approval of Non-executive director remuneration	Ρ	62,231,832	62,104,206 99.79%	73,177 0.12%	340,000	54,449 0.09%	63,013,783 99.88%	73,177 0.12%	407,479	Carried
7 Approval of prior issue of Placement Shares	Ρ	62,572,299	62,456,748 99.82%	81,960 0.13%	0	33,591 0.05%	63,445,269 99.87%	81,960 0.13%	0	Carried

